The Valley Desk

ArticleFuture oncology (London, England)Published

Fixed-duration ibrutinib-venetoclax for first-line treatment of patients with chronic lymphocytic leukemia: the REALITY-WW prospective real-world study cohort

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Future oncology (London, England)
Published
Subject terms
Humans; Sulfonamides; Piperidines; Adenine; Antineoplastic Combined Chemotherapy Protocols; Treatment Outcome; Prospective Studies; Aged; Middle Aged; Female; Male; Leukemia, Lymphocytic, Chronic, B-Cell
PubMed ID
41175112
PubMed Central ID
PMC12688257
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal